Skip to main content
Journal of Extracellular Vesicles logoLink to Journal of Extracellular Vesicles
. 2022 May 8;11(5):e12219. doi: 10.1002/jev2.12219

Erratum: A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

PMCID: PMC9081484  PMID: 35527350

Jiang, L., Driedonks, T. A. P., Jong, W. S. P., Dhakal, S., Bart van den Berg van Saparoea, H., Sitaras, I., Zhou, R., Caputo, C., Littlefield, K., Lowman, M., Chen, M., Lima, G., Gololobova, O., Smith, B., Mahairaki, V., Riley Richardson, M., Mulka, K. R., Lane, A. P., Klein, S. L., … Witwer, K.W. (2022). A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants. Journal of Extracellular Vesicles, 11(3), e12192. https://doi.org/10.1002/jev2.12192

In the initially published version of this article, in both the conflict of interest and author contributions sections, the author's name was incorrectly mentioned as “Joseph L. Mankowski” whereas it should be “Joen Luirink”.


Articles from Journal of Extracellular Vesicles are provided here courtesy of Wiley

RESOURCES